These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 39367493

  • 1. Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in muscle-invasive bladder cancer.
    Wang Y, Song W, Feng C, Wu S, Qin Z, Liu T, Ye Y, Huang R, Xie Y, Tang Z, Wang Q, Li T.
    J Transl Med; 2024 Oct 04; 22(1):900. PubMed ID: 39367493
    [Abstract] [Full Text] [Related]

  • 2. Fibronectin-1: A Predictive Immunotherapy Response Biomarker for Muscle‑Invasive Bladder Cancer.
    Zhang X, Liu H, Zhang J, Wang Z, Yang S, Liu D, Liu J, Li Y, Fu X, Zhang X.
    Arch Esp Urol; 2023 Feb 04; 76(1):70-83. PubMed ID: 36914422
    [Abstract] [Full Text] [Related]

  • 3. Blockade of DC-SIGN+ Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer.
    Hu B, Wang Z, Zeng H, Qi Y, Chen Y, Wang T, Wang J, Chang Y, Bai Q, Xia Y, Wang Y, Liu L, Zhu Y, Dai B, Guo J, Xu L, Zhang W, Xu J.
    Cancer Res; 2020 Apr 15; 80(8):1707-1719. PubMed ID: 32060149
    [Abstract] [Full Text] [Related]

  • 4. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
    Zhang Y, Zhang X, Huang X, Tang X, Zhang M, Li Z, Hu X, Zhang M, Wang X, Yan Y.
    Stem Cell Res Ther; 2023 Feb 01; 14(1):15. PubMed ID: 36721217
    [Abstract] [Full Text] [Related]

  • 5. Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks.
    Xu Y, Sun X, Liu G, Li H, Yu M, Zhu Y.
    Front Immunol; 2023 Feb 01; 14():1301157. PubMed ID: 38299148
    [Abstract] [Full Text] [Related]

  • 6. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
    Jiang W, Zhu D, Wang C, Zhu Y.
    Cancer Med; 2020 Apr 01; 9(8):2774-2790. PubMed ID: 32096345
    [Abstract] [Full Text] [Related]

  • 7. Construction of an Immune-Associated Gene-Based Signature in Muscle-Invasive Bladder Cancer.
    Shen C, Xu T, Sun Y, Wang L, Liang Z, Niu H, Jiao W, Wang Y.
    Dis Markers; 2020 Apr 01; 2020():8866730. PubMed ID: 33456631
    [Abstract] [Full Text] [Related]

  • 8. Dynamic landscape of m6A modifications and related post-transcriptional events in muscle-invasive bladder cancer.
    Zhang L, Chen Z, Sun G, Li C, Wu P, Xu W, Zhu H, Zhang Z, Tang Y, Li Y, Li Y, Xu S, Li H, Chen M, Xiao F, Zhang Y, Zhang W.
    J Transl Med; 2024 Oct 08; 22(1):912. PubMed ID: 39380003
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long noncoding RNA MIR31HG and its splice variants regulate proliferation and migration: prognostic implications for muscle invasive bladder cancer.
    Wu S, Nitschke K, Worst TS, Fierek A, Weis CA, Eckstein M, Porubsky S, Kriegmair M, Erben P.
    J Exp Clin Cancer Res; 2020 Dec 17; 39(1):288. PubMed ID: 33334367
    [Abstract] [Full Text] [Related]

  • 12. Overexpression of long non-coding RNA TUG1 predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade muscle-invasive bladder cancer.
    Iliev R, Kleinova R, Juracek J, Dolezel J, Ozanova Z, Fedorko M, Pacik D, Svoboda M, Stanik M, Slaby O.
    Tumour Biol; 2016 Oct 17; 37(10):13385-13390. PubMed ID: 27460088
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Utility of SAM68 in the progression and prognosis for bladder cancer.
    Zhang Z, Yu C, Li Y, Jiang L, Zhou F.
    BMC Cancer; 2015 May 06; 15():364. PubMed ID: 25944080
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Crosstalk between Mesenchymal Stem Cells and Cancer Stem Cells Reveals a Novel Stemness-Related Signature to Predict Prognosis and Immunotherapy Responses for Bladder Cancer Patients.
    Ma L, Chen H, Yang W, Ji Z.
    Int J Mol Sci; 2023 Mar 01; 24(5):. PubMed ID: 36902193
    [Abstract] [Full Text] [Related]

  • 18. Single-cell and bulk RNA-sequence identified fibroblasts signature and CD8 + T-cell - fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine learning: bioinformatics multi-omics study.
    Li J, Kong Z, Qi Y, Wang W, Su Q, Huang W, Zhang Z, Li S, Du E.
    Int J Surg; 2024 Aug 01; 110(8):4911-4931. PubMed ID: 38759695
    [Abstract] [Full Text] [Related]

  • 19. Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer.
    Pagliarulo F, Cheng PF, Brugger L, van Dijk N, van den Heijden M, Levesque MP, Silina K, van den Broek M.
    Front Immunol; 2021 Aug 01; 12():793992. PubMed ID: 35145509
    [Abstract] [Full Text] [Related]

  • 20. Predictive Value of CD44 in Muscle-Invasive Bladder Cancer and Its Relationship with IL-6 Signaling.
    Wu CT, Lin WY, Chen WC, Chen MF.
    Ann Surg Oncol; 2018 Nov 01; 25(12):3518-3526. PubMed ID: 30128900
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.